PCI for STEMI Ari de la Hera, M.D..

Slides:



Advertisements
Similar presentations
Degli Studi e dei Registri: sul Territorio
Advertisements

Door to Balloon Times: Achieving 90 Minutes and Less.
Regional AMI Care: Bridging the Rural Health Care Gap Darren B. Bean, MD University of Wisconsin Emergency Medicine/Medflight Director UW Level 1 Heart.
Optimal Timing of PCI in ACS Patrick Hildbrand. Trends and Prognosis in ACS Furman MI, JACC 2001, 37: Hospital 1 year.
Canadian Cardiovascular Society Antiplatelet Guidelines
Regional Systems of Care to Optimize Timeliness of Reperfusion Therapy for STEMI: The Mayo Clinic Protocol Henry H. Ting, MD, MBA Associate Professor of.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
STEMI: What’s the Rush? STEMI: What’s the Rush? William Phillips, MD, FACC, FSCAI Director of Cardiology CMMC A PCI Center perspective.
“Acute Coronary Syndromes: Trials & Tribulations" Will Southern, M.D., M.S. Director of Hospitalist Services Associate Medical Director Weiler Division.
Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
Masoudi FA et al J Am Coll Cardiol (Published online 27 November 2008) CVN Weekly Interventional Update December 8, 2008 Jeffrey J. Popma and Christopher.
An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,
Management of Stable Angina SIGN 96
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
Ten Points to Remember from the 2007 STEMI Guideline Update Based on the 2007 Focused Update of the 2004 Guidelines for the Management of Patients With.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
Advanced Cardiovascular Intervention 2009 Timings in PPCI: Have we learnt the lessons from our European Colleagues? Peter F Ludman.
BLEEDING AND ACUTE CORONARY SYNDROMES Cardiac Catherization Conference Syed Raza MD Cardiology Fellow VCU Medical Center 06/02/2011.
Acute STEMI: current approach
Ambulance Victoria and MonashHEART Acute Myocardial Infarction (Mon-AMI) 12 lead ECG project. An update On behalf of the MonAMI Team A Hutchison, Y Malaiapan,
Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.
Giovanni Maria Santoro S. C. Cardiologia Ospedale San Giovanni di Dio Firenze Gestione del paziente con stent coronarico. Il mantenimento della doppia.
ACC Guidelines Webcast: Highlights from the 2007 STEMI Focused Update Based on the 2007 Focused Update of the ACC/AHA Guidelines for the Management of.
Management Of AMI Does time matter?? What is the best strategy: PPCI Vs TT.
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Infarct transmurality and infarct size assessed by delayed enhancement magnetic resonance imaging: Association.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.
Enoxaparin in primary PCI From FINESSE to ATOLL G. Montalescot Institut de Cardiologie Pitié-Salpêtrière Hospital Paris, France The FINESSE Trial is supported.
Managing AMI – much work still to do? MONDAY, 28 th FEBRUARY – SESSION 3 Patrick Goldstein EXPERTS WORKSHOP ON EARLY TREATMENT STRATEGIES FOR ACUTE MYOCARDIAL.
RACE: Reperfusion of acute myocardial infarction in North Carolina emergency departments Christopher Granger, MD Director, Cardiac Care Unit Duke University.
Bivalirudin: Myths vs Reality? Dr Reman McDonagh Nycomed UK Ltd Conflict of Interest: Senior Manager working for Nycomed UK Ltd.
Case study - patient presenting with newly diagnosed NVAF with prior CAD Full Prescribing Information is provided at the end of this presentation EUAPI581k;
{ Challenging Case Presentations From South Texas Methodist Hospital REGIONAL SYSTEMS OF CARE DEMONSTRATION PROJECT: MISSION: LIFELINE™ STEMI SYSTEMS ACCELERATOR.
TAHAR EL KANDOUSSI, SARA ECHERKI, NAWAL DOGHMI, MOHAMED CHERTI. SEcurite de l’Echocardiographie de stress : plutôt l’effort. Cardiology B Department, Ibn.
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2007 Focused Update of the ACC/AHA 2004 Guidelines.
Telemedicine To Expedite Patient’s Transfer: The Introduction of the Videophone Lowell Satler, MD Washington Hospital Center.
Prehospital NSTEMI Patient Assessment and Treatment
Challenging Case Presentations From South Texas Methodist Hospital
Polypharmacy Anticoagulation: AF meets PCI
Eva Kline-Rogers RN, NP, AACC University of Michigan
Transradial Intervention as Access of Choice in STEMI
How to Minimize Bleeding in STEMI Patients Outline: -Know about bleeding -Think about consequences of bleeding -Identify bleeding risk factors -Maximize.
Novel oral anticoagulants in comparison with warfarin
Bleeding and cancer risk in patients with vascular disease COMPASS Steering Committee and Investigators.
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Figure 2 Ischaemic and bleeding outcomes in the major clinical trials
% Heparin + GPI IIb/IIIa Bivalirudin +
Impact of Platelet Reactivity Following Clopidogrel Administration
Mancini JG, et al. Am J Cardiol.
What oral antiplatelet therapy would you choose?
Presents to PCI-capable hospital and undergoes
Nat. Rev. Cardiol. doi: /nrcardio
Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care  Marc Cohen, MD  Mayo Clinic Proceedings 
Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.
Bleeding and Outcomes OASIS Registry, OASIS - 2, CURE (n=34,146) Death
Presentation transcript:

PCI for STEMI Ari de la Hera, M.D.

ED physician activates the Cath Lab Single call to activate the Cath Lab Cath Lab operational within 20 minutes of activation Real time data feedback for case review  Having attending cardiologist always on site  Prehospital ECG to activate Cath Lab while patient is en route N Engl J Med 2006;355:

Meta-analysis: Facilitated PCI vs Primary PCI 1.03 ( ) 3.07 ( ) 1.43 ( ) 1.03 ( ) MortalityReinfarctionMajor Bleeding Fac. PCI Better PPCI Better Fac. PCI Better PPCI Better Fac. PCI Better PPCI Better Keeley E, et al. Lancet 2006;367: ( ) 1.71 ( ) 1.51 ( ) Lytic alone N=2953 IIb/IIIa alone N=1148 Lytic +IIb/IIIa N=399 All (N=4500) 1.40 ( ) 1.81 ( )

Acetaminophen, ASA, tramadol, narcotic analgesics (short term) COX-2 Selective NSAIDs Nonacetylated salicylates Non COX-2 selective NSAIDs NSAIDs with some COX-2 activity Stepped Care Approach To Pharmacologic Therapy for Musculoskeletal Symptoms with Known Cardiovascular Disease or Risk Factors for Ischemic Heart Disease Select patients at low risk of thrombotic events Prescribe lowest dose required to control symptoms Add ASA 81 mg and PPI to patients at increased risk of thrombotic events * Regular monitoring for sustained hypertension or worsening of prior blood pressure control), edema, worsening renal function, or gastrointestinal bleeding. If these events occur, consider reduction of the dose or discontinuation of the offending drug, a different drug, or alternative therapeutic modalities, as dictated by clinical circumstances. * Addition of ASA may not be sufficient protection against thrombotic events Antman EM, et al. J Am Coll Cardiol Published ahead of print on December 10, Available at